A Phase I Study of Alpelisib in Combination with Trastuzumab and LJM716 in Patients with PIK3CA-Mutated HER2-Positive Metastatic Breast Cancer.

Komal JhaveriJoshua Z Drago Payal Deepak ShahRui WangFresia ParejaFanni RatzonAlexia IasonosSujata PatilNeal X Rosen Monica N FornierNancy T SklarinSarat Chandarlapaty Shanu Modi

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)

Combination treatment with alpelisib, trastuzumab, and LJM716 was limited by gastrointestinal toxicity. Further efforts are warranted to target the PI3K pathway in HER2+ MBC.

Keyphrases

metastatic breast cancer
epidermal growth factor receptor
oxidative stress
quality improvement
combination therapy
protein kinase
smoking cessation
wild type